Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
Holding OTLK?
Track your performance easily
OTLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.87 - $12.85
Previous Close$1.48
Volume693.42K
Average Volume (3M)1.63M
Market Cap
$35.01M
Enterprise Value$35.71M
Total Cash (Recent Filing)$32.02M
Total Debt (Recent Filing)$32.72M
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Dec 19, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.75
Shares Outstanding23,655,636
10 Day Avg. Volume1,771,709
30 Day Avg. Volume1,625,618
Standard Deviation0.38
R-Squared0.00418
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$19.50Price Target Upside1263.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Outlook Therapeutics News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/29/24
Bulls Say, Bears Say
Bulls Say
Financial StabilityOutlook's cash position is sufficient to support the BLA submission and the 6 months review period.
Market PotentialOutlook could disrupt over half the ocular anti-VEGF injection market by volume with what could emerge as the first FDA-approved intravitreal formulation of bevacizumab.
Regulatory ApprovalsThe company recently received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA (bevacizumab gamma) for the treatment of wet AMD.
Bears Say
Clinical TrialsONS-5010 misses key endpoint of NORSE 8 trial, raising concerns about its efficacy.
Product PipelineONS-5010 is the company's sole active development program, highlighting a lack of diversification.
Regulatory ChallengesThe FDA issued a Complete Response Letter for the BLA of ONS-5010, indicating regulatory obstacles.
---
Ownership Overview
37.80% Insiders
4.87% Mutual Funds
19.26% Other Institutional Investors
31.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $12.85 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Currently, no data Available
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Dec 19, 2024 which is 2 days ago.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.033 by $0.203.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 23,655,636 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.033. Following the earnings report the stock price went down -5.29%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Among the largest hedge funds holding Outlook Therapeutics’s share is Woodline Partners LP. It holds Outlook Therapeutics’s shares valued at 809K.
---
Outlook Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (1263.64% Upside)
$19.50 (1263.64% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 722.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.95%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Earnings Call
Q3 2024
0:00 / 0:00
---
OTLK Stock 12 Month Forecast
Average Price Target
$19.50
▲(1263.64% Upside)
Technical Analysis
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-39.21%
reiterated a buy rating 4 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -39.21% per trade.
---